Topic: Prepubescent

The guests explain why clinical trials focused on older women while the target market for the vaccine is children aged 9 to 12. They discuss the risks of administering the vaccine to those already exposed to HPV and criticize the American College of Obstetricians and Gynecologists for not recommending pre-screening.

Following Eileen Iorio's departure, Kim Mack Rosenberg discusses the risks of vaccinating prepubescent children during periods of significant hormonal change. She argues that the robust immune response seen in younger children may actually lead to more frequent or severe negative reactions.